The GLP is committed to full transparency. Download and review our 2019 Annual Report

Personalized cancer treatments struggling to overcome patient deaths, severe side effects

| | September 8, 2016
dividing cancer cells
Image via Singularity Hub.
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The idea is tantalizing: Reengineer a patient’s own immune cells to attack the cancer that’s killing her. Scientists have proven it can be done, curing patients of…blood cancers.

But faith in this approach, dubbed CAR-T immunotherapy, has been [recently] shaken….

To be sure, there’s still excitement in the field.

“I think the story line today is, CAR-T is really walking a fine line,” said Brad Loncar…“A year ago, there was definitely exuberance. But now, we’re on the precipice of people pulling back.”

Scaling up is a tricky prospect for CAR-T therapy. Increasing the capacity to manufacture a standard biologic drug might involve bumping up the size of a bioreactor so it can pump out…5,000 liters…But CAR-T therapy is so highly personalized that manufacturers have to effectively build 5,000 one-liter bioreactors….

“I think it’ll take us years, though certainly not decades, to get to the point where we have near-complete automation,” [Bruce] Levine said.

[C]ell therapies will need both clinical success and commercialization to keep up the momentum, Loncar said.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: Hurdles abound in race to bring customized cancer treatments to masses

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend